Get access

Immune Modulation with Interleukin-21

Authors


Address for correspondence: William E. Carson III, OSU Comprehensive Cancer Center, The Ohio State University, N924 Doan Hall, 410 W. 10th Ave., Columbus, OH 43210. Voice: 614-292-5819; fax: 614-688-4366. william.carson@osumc.edu

Abstract

Interleukin 21 (IL-21) is produced by activated CD4+ T cells. The IL-21R shares the common receptor gamma-chain with IL-2, IL-4, IL-7, IL-9, and IL-15, is widely expressed on immune cells, and mediates a variety of effects on the immune system. IL-21 enhances the proliferation, antigen-induced activation, clonal expansion, IFN-γ production, and cytotoxicity of NK cells and T cells. The antitumor actions of IL-21 have been variously attributed to NK cell and CD8+ T cell cytotoxicity, CD4+ T cell help, NKT cells, and the antiangiogenic properties induced by IFN-γ secretion. In clinical trials IL-21 has been well tolerated and induces a unique pattern of immune activation. IL-21 is therefore an excellent candidate for use in immune therapy.

Ancillary